Should You Buy BridgeBio Pharma Inc (BBIO) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Buy now for a beginner, long-term investor. BBIO is in a broader uptrend (bullish moving-average stack) with strong Wall Street support and accelerating commercial traction (revenue surge from Attruby). Short-term momentum is slightly soft (negative MACD), but options positioning is strongly bullish and the medium/long-term setup remains attractive—so it’s a good buy right now rather than waiting for a perfect dip.
Technical Analysis
Trend is bullish overall: SMA_5 > SMA_20 > SMA_200 indicates a sustained uptrend. However, near-term momentum is cooling: MACD histogram is negative (-0.106) and expanding lower, implying mild short-term weakness/pullback risk. RSI_6 at ~53 is neutral (not overbought). Price (76.8) is just below the pivot (77.643); key levels: support S1 ~74.76 then S2 ~72.97; resistance R1 ~80.53 then R2 ~82.31. Net read: long-term trend up, short-term consolidation.
Analyst Ratings and Price Target Trends
Recent trend is decisively positive: multiple firms raised price targets through late 2025 (e.g., Goldman to $100 from $55; TD Cowen to $95 from $60; others to ~$80s) alongside consistent Buy/Overweight/Outperform ratings. In January 2026, Barclays initiated coverage Overweight with a $157 target, reinforcing a bullish Street stance. Wall Street pros: strong commercial momentum + multiple upcoming catalysts + perceived sector tailwinds. Cons: competition (notably in certain oncology/KRAS areas) and continued losses until revenue scale drives profitability. Politician/congress activity: no recent congress trading data available; hedge fund/insider trend data shows neutral activity recently.
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 79.100
Current: 79.100
